Common immune checkpoint targets that have been reported for having a promising effect, including Lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and ITIM domain (TIGIT), and indoleamine 2,3-dioxygenase [23], have presented significance with B4GALNT1 in several cancers. This evidence concerns the gene IDO2 and cancer.